



Routine viral load (VL) monitoring for targeted adherence support among antiretroviral therapy (ART) patients in a resource-limited setting, Swaziland

8th International Conference on HIV Treatment and Prevention Adherence

June 02 - June 04, 2013

Eden Roc Renaissance Miami Beach - Miami Beach, Florida

PRESENTER: Dr Charles Azih, MD, MPH

Co-authors

Velephi Okello¹, Sithembile Dlamini¹, Kiran Jobanputra², Lucy Anne Parker², Jacqueline Papo³, Charles Azih¹

1. Swaziland National AIDS Program, MoH
2. Médecins Sans Frontières, Swaziland
3. Clinton Health Access Initiative, Swaziland



Introduction I



- Swaziland (popula 1.1 m)
- Adult (18-49yrs) HIV prevalence of 31% (SHIMS 2012)
- ~90,000 clients on ART (Mar 2013)
- >80% retention at 24months
- **4-6monthly routine CD4 monitoring (currently)**

Introduction II

- In May 2012, the Swaziland National AIDS Programme, in partnership with Medecins sans Frontieres, (MSF) began implementation of **Routine Viral Load (VL) monitoring** in Shiselweni region.

Swaziland / Shiselweni region



- Generic laboratory-based VL platform (Biocentric), at regional lab level.
- With detectability threshold at **100copies/ml**

Introduction III

- **Eligibility for routine VL monitoring:** on ART for at least 6 months.
- Patients with detectable VL then receive **enhanced adherence interventions** consisting of:
 - Baseline adherence and clinical assessment by nurse (with treatment of Opportunistic Infections)
 - 1-monthly drug pick-ups (from 3monthly pick-up)
 - **Stepped-up adherence counselling** (x 3 sessions)
 - solution-focused counselling intervention,
 - provided by lay counsellors (Expert Clients),
 - each counselling session lasting 30-45 minutes.

Rational

Routine VL monitoring enhances timely detection of treatment failure, & can help identify patients with adherence problems, thus permitting adherence interventions to prevent acquired resistance.

Objectives

- To identify determinants of detectable VL
- To define high-risk groups that may benefit from stepped-up adherence support
- To make recommendations for programming

Methodology 1

- Operational Research
- Involving 23 clinics and 2 health centres in 3 health zones of Shiselweni region, Swaziland
- Study period – May 2012 – March 2013
- Study subjects – all HIV+ clients on ART for =>6 months and have 1st VL test done
- Outcome measure – viral detectability following ART for =>6 months

Methodology 2

- We analysed lab records of 7689 patients who received 1st routine VL test during study period.
- Among these, 2089 were linked electronically with the national ART database using unique patient ID.
- Descriptive analysis and multivariable logistic regression were used to explore the relationship between VL and gender, age, time on ART, recent CD4 count & WHO stage.
- Statistical analysis were performed using Stata/SE (StataCorp, Texas, U.S.A.) Version 12.1.

Lab and staff




Description of the population

- 7689 patients
- 4979 (65%) female
- Median age 38 years (IQR 30 – 48)
- Median time since ART initiation 3years and 5months (IQR 2–5 years)

Findings

Viral detectability among study cohort



**1098 (14%)
patients had a
detectable VL.**

■ Undetectable ■ 101-1000 copies/ml ■ >1000 copies/ml


Viral detectability by sex

	Undetectable (N, %)	Detectable (N, %)
Male	2290 (84.5%)	420 (<u>15.5%</u>)
Female	4301 (86.4%)	678 (<u>13.6%</u>)
Total	65921(85.7%)	1098 (14.3%)

Although small, we noted a significantly higher rate of detectability in men (p 0.023)

Viral detectability by age


Proportion with detectable VL was higher among children/adolescents (28.7% in patients aged ≤ 20 yrs, compared to 12.6% in those aged >20 , $p < 0.001$).



Viral detectability by most recent CD4 count

■ Undetectable ■ Detectable


Patients with lower CD4 were more likely to have detectable VL, $p < 0.001$



Viral detectability by most recent WHO staging

■ Undetectable ■ Detectable

Patients on WHO stages III/IV were more likely to have detectable VL, $p=0.001$



Viral detectability & time on ART


	Undetectable (N, %)	Detectable (N, %)
Time on ART		
Median	3.4 yrs	3.4 yrs
Interquartile Range	(2 yrs – 5.2 yrs)	(2 yrs – 5 yrs)

Re-suppression following adherence interventions

- Among 200 “detectable patients” who had repeat VL test, 95 (47.5%) became undetectable following stepped-up adherence counseling (**re-suppression**).

- Level of **re-suppression** was significantly less among patients ≤ 20 years old than those >20 years old ($p=0.001$).
- 41% of men vs 49% of women got re-suppressed ($p=0.223$)

Viral re-suppression by age



Conclusions 1

- Routine VL monitoring can be beneficial in resource-constrained settings—to identify those who may benefit from targeted adherence interventions.
- Children and adolescents are more likely to have detectable VL, and are less likely to re-suppress following stepped-up adherence interventions.
- Men are more likely than women to have detectable VL, and are less likely to re-suppress following adherence interventions.

Conclusions 2

- These groups could benefit from routine, early and more frequent VL monitoring, to detect adherence problems early; with tailored interventions to improve adherence and achieve viral re-suppression.

Study Limitations

- An operational research – not RCT design
- Utilising laboratory-based data mainly
- Did not control for some baseline patient characteristics, e.g. CD4 count at initiation
- Adherence counselling interventions provided mainly by lay counsellors with limited skills

Acknowledgements

- Médecins Sans Frontières
- Swaziland National AIDS Programme
- Regional Health Management Team of Shiselweni
- The health care workers of Shiselweni
- Our patients



THANK YOU